Post-Market Surveillance Study of ALK-Positive Advanced NSCLC Participants Treated With Iruplinalkib

CIK Cell Transfusion Plus Gefitinib As Second Or Third-Line Treatment for Advanced Adenocarcinoma Non-Small Cell Lung Cancer

NCT01871480 ·Status: TERMINATED ·Phase: PHASE2

Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)

NCT02679170 ·Status: COMPLETED

A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

NCT06254599 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung Cancer

NCT01500824 ·Status: WITHDRAWN ·Phase: PHASE2

Real-world Study of Local Therapy Changes During 1L Lorlatinib in Unresectable ALK+ NSCLC

NCT06690541 ·Status: NOT_YET_RECRUITING

Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.

NCT02292550 ·Status: COMPLETED ·Phase: PHASE1

Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC

NCT06092086 ·Status: RECRUITING ·Phase: PHASE2

Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

NCT04318938 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

An Exploratory Clinical Study of TILs in the Treatment of Recurrent / Refractory Non-small Cell Lung Cancer (NSCLC)

NCT04919616 ·Status: UNKNOWN ·Phase: EARLY_PHASE1

Induction Lorlatinib in Stage III Non-small Cell Lung Cancer

NCT05740943 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC

NCT06951464 ·Status: RECRUITING ·Phase: PHASE2

Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLC

NCT05244213 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants

NCT02075840 ·Status: COMPLETED ·Phase: PHASE3

Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer

NCT05241028 ·Status: RECRUITING ·Phase: PHASE2

Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy

NCT06862869 ·Status: RECRUITING

A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

NCT03546894 ·Status: COMPLETED

Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer

NCT03647111 ·Status: RECRUITING

Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer

NCT05132218 ·Status: UNKNOWN

Erlotinib as Neoadjuvant Treatment in Patients With Stage ⅢA N2 NSCLC With Activating EGFR Mutation.

NCT01217619 ·Status: COMPLETED ·Phase: PHASE2

A Phase Ib Study of GC101 in NSCLC

NCT06473961 ·Status: RECRUITING ·Phase: PHASE1

The Efficacy and Safety of Ensartinib As Adjuvant Therapy in Stage I ALK-positive NSCLC Patients with High Risk Factors

NCT06772610 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients

NCT06564324 ·Status: RECRUITING ·Phase: PHASE3

Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements

NCT05987644 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

NCT04647110 ·Status: COMPLETED

Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC

NCT06569420 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3